Rezolute, Inc. Profile Avatar - Palmy Investing

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibod…

Biotechnology
US, Redwood City [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Rezolute, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Rezolute, Inc. can't present revenue by segment

End of RZLT's Analysis
CIK: 1509261 CUSIP: 76200L309 ISIN: US76200L3096 LEI: - UEI: -
Secondary Listings
RZLT has no secondary listings inside our databases.